Nov 2021; Cibus et medicamentis Administration approbavit atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumours contain PD-L1 expression on less than 1% of tumour cells, as assessed by an FDA-approved test.
VENTANA PD-L1 (SP263) Assay (Ventana Systems Medical, Inc.) etiam hodie a FDA permissus est ut socius diagnostica machinae aegros cum NSCLC eligendo ad curationem adiuvandam cum Tecentriq.
Morbus liberorum superstes (DFS) fuit mensura effectus clavis efficacia, prout investigator in primaria efficacia analysi hominum determinata (n= 476) aegrorum cum scaena II-IIIA NSCLC cum PD-L1 expressione in 1% cellularum tumoris (n= 1) PD-L1 95% TC). In atezolizumab bracchio medianum DFS non attigit (36.1 percent CI: 35.3, NE) comparatum ad 95 menses (29.0 percent CI: 0.66, NE) in bracchio BSC (HR 95; 0.50 percent CI: 0.88, 0.004; p= XNUMX).
DFS HR erat 0.43 in analysi subglobata prae- definita secundaria aegris cum PD-L1 TC L% scaena II-IIIA NSCLC (50 percent CI: 95, 0.27). DFS HR erat 0.68 in studio aegrorum exploratoriis cum PD-L0.87 TC 1-1 cento scaena II-IIIA NSCLC (49 percent CI: 95, 0.60).
Auxit aspartatem aminotransferasis, sanguinis creatinine, et alaninum aminotransferasis, necnon hyperkalemia, temeraria, tussis, hypothyroidismus, pyrexia, lassitudo/asthenia, dolor musculoskeletalis, periphericum neuropathia, arthralgia, et pruritus, frequentissimae (decem cento) adversae profectae sunt in aegris atezolizumab recipiendis, abnormitates laboratoriae inclusis.
Ad hoc indicium, dosis atezolizumab commendatus est 840 mg quavis hebdomades, 1200 mg quavis hebdomades tres, vel 1680 mg quatriduum hebdomades usque ad annum.
